Last week @fda sends out clarification on who can and cannot compound #glp1 like #tirzeaptide and #semaglutide and this week ProRx 503b shuts down GLP 1 compounding while @martymakary is photographed holding bootleg # Dr Jesse Morse explains why BPC 157 will never receive FDA approval despite its potential to accelerate healing and recovery from injuries. >> More FDA July 2026 Peptide Meeting: What Patients Need to Know About Access, Approval, and Safety Meto blog FDA Puts BPC 157, TB 500, and 5 Other Peptides Under the Microscope: What Prescribers Need to Know About the 503A Review Lengea